Back to CVE records
High 8.7Published Mar 30, 2026

CVE-2026-3321A vulnerability of authorization bypass through user-controlled key in the 'console-survey/api/v1/answer/{EVENTID}/{TIMESTAMP}/' endpoint.

Updated under an hour ago ()

Does this affect you?

It lists no affected products yet. Add what you run and Signals checks it as products are added.

No exploitation reported and no EPSS estimate yet.

A vulnerability of authorization bypass through user-controlled key in the 'console-survey/api/v1/answer/{EVENTID}/{TIMESTAMP}/' endpoint. Exploiting this vulnerability would allow an unauthenticated attacker to enumerate event IDs and obtain the complete Q&A history. This publicly exposed data may include IDs, private URLs, private messages, internal references, or other sensitive information that should only be exposed to authenticated users. In addition, the leaked content could be exploited to facilitate other malicious activities, such as reconnaissance for lateral movement, exploitation of related systems, or unauthorised access to internal applications referenced in the content of chat messages.

CVSS
8.7 HIGH (v4.0, NVD)CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:N/VA:N/SC:L/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Weakness (CWE)
CWE-639
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
Not loaded for this CVE
Assigned by
Not given
NVD analysis
Deferred
Record last updated
Jun 17, 2026
First seen by InfoSec Signals
Oct 9, 2026

Affected products

No affected products are listed yet.

References

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.